Amycretin is a novel, unimolecular GLP-1 and amylin receptor agonist. The aim of this study was to investigate the safety, tolerability, pharmacokinetics, and effects on bodyweight of subcutaneous ...

Animal studies support that theory. GLP-1 drugs reduce inflammation in the brain and interfere with reward pathways linked to ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

Originally designed to manage type 2 diabetes, the GLP-1 drug Ozempic has become a global phenomenon for its off-label weight ...

Historically, managing type 2 diabetes in advanced chronic kidney disease (CKD) has been challenging due to a lack of therapies and increased risks for adverse events.

Glucagon-like peptide-1 receptor agonists (GLP-1RA) drugs, such as Ozempic and Wegovy, are often referred to as "miracle ...

GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

Mouse livers were engineered via a one-time genome editing to secrete a GLP-1, cutting weight gain and improving glucose ...

Researchers create a one-time genome editing introducing a GLP-1 receptor agonist, resulting in long-term appetite ...